NeuroOne Medical Technologies Corporation (NMTC)
| Market Cap | 28.36M -2.2% |
| Revenue (ttm) | 12.72M +120.9% |
| Net Income | -6.64M |
| EPS | -0.83 |
| Shares Out | 8.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,101 |
| Open | 3.240 |
| Previous Close | 3.250 |
| Day's Range | 3.220 - 3.380 |
| 52-Week Range | 3.075 - 6.960 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 9.93 (+201.82%) |
| Earnings Date | May 12, 2026 |
About NMTC
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a ... [Read more]
Financial Performance
In fiscal year 2025, NMTC's revenue was $12.10 million, an increase of 250.35% compared to the previous year's $3.45 million. Losses were -$3.61 million, -70.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NMTC stock is "Strong Buy." The 12-month stock price target is $9.93, which is an increase of 201.82% from the latest price.
News
NeuroOne Medical Technologies Transcript: Planet MicroCap Las Vegas 2026
Innovative thin film and wire electrode technologies are driving less invasive, dual-purpose treatments for epilepsy and chronic pain, with strong clinical results and expanding market adoption. Financially stable with a cash runway through 2026, the company is poised for growth in new indications and international markets.
NeuroOne Medical Technologies Slides: Corporate presentation
NeuroOne Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
NeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg
Ladenburg adjusted the firm’s price target on NeuroOne Medical (NMTC) to $8 from $1.60 and keeps a Buy rating on the shares. It cites the one-for-six reverse stock split for…
NeuroOne Medical Technologies Earnings Call Transcript: Q2 2026
Q2 FY2026 saw 72% YoY product revenue growth to $2.4M, driven by OneRF Brain Ablation sales and strong clinical adoption. Guidance for FY2026 remains $10.5M, excluding new product launches, with international expansion and drug delivery commercialization targeted for late 2026.
NeuroOne Medical Technologies Earnings release: Q2 2026
NeuroOne Medical Technologies released its Q2 2026 earnings on May 12, 2026, summarizing the period's financial results.
NeuroOne Medical Technologies Quarterly report: Q2 2026
NeuroOne Medical Technologies has published its Q2 2026 quarterly earnings report on May 12, 2026.
NeuroOne Medical Technologies trading halted, news pending
19:50 EDT NeuroOne Medical (NMTC) Technologies trading halted, news pending
NeuroOne Medical Technologies Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
A novel thin film electrode platform is driving growth in neurological device markets, with strong clinical outcomes, expanding partnerships, and a robust financial outlook. Key catalysts include new product launches, international expansion, and potential partnership deals in 2026.
NeuroOne Medical Technologies Transcript: Investor update
Four FDA-cleared devices target large neurological and pain markets, with strong partnerships and a unique thin-film platform driving growth. Fiscal 2026 revenue is guided at $10.5 million, with catalysts including new product launches, international expansion, and potential partnerships.
NeuroOne Medical Technologies Slides: Corporate presentation
NeuroOne Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
NeuroOne Medical Technologies Proxy statement: Proxy Filing
NeuroOne Medical Technologies filed a proxy statement on March 9, 2026, providing details for shareholder voting and corporate governance matters.
NeuroOne Medical initiated with a Buy at JonesResearch
JonesResearch analyst Justin Walsh initiated coverage of NeuroOne Medical (NMTC) with a Buy rating and $1.50 price target With a portfolio of four FDA-cleared products for the monitoring, recording, s...
NeuroOne Medical Technologies Proxy statement: Proxy Filing
NeuroOne Medical Technologies filed a proxy statement on February 27, 2026, providing details for shareholder voting and corporate governance matters.
NeuroOne Medical Technologies Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose sequentially but was down year-over-year due to a prior large stocking order. Guidance for fiscal 2026 targets at least $10.5 million in sales, a 17% increase, with strong adoption of new products and ongoing strategic partnership discussions.
NeuroOne Medical Technologies Earnings release: Q1 2026
NeuroOne Medical Technologies released its Q1 2026 earnings on February 17, 2026, summarizing the period's financial results.
NeuroOne Medical Technologies Quarterly report: Q1 2026
NeuroOne Medical Technologies has published its Q1 2026 quarterly earnings report on February 17, 2026.
NeuroOne Medical Technologies Slides: Corporate presentation
NeuroOne Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on December 22, 2025.
NeuroOne Medical Technologies Earnings Call Transcript: Q4 2025
Record product sales and improved margins drove a turnaround, with Q4 revenue up 907% year-over-year and net loss reduced by 71% for the year. FDA clearances, new product launches, and expanded partnerships position the company for continued growth in 2026.
NeuroOne Medical Technologies Earnings release: Q4 2025
NeuroOne Medical Technologies released its Q4 2025 earnings on December 17, 2025, summarizing the period's financial results.
NeuroOne Medical Technologies Annual report: Q4 2025
NeuroOne Medical Technologies has published its Q4 2025 annual report on December 17, 2025.
NeuroOne Medical Technologies Transcript: Investor Update
Achieved $9.1M in product revenue and $3M in license revenue, expanded key partnerships, and advanced FDA-cleared products for epilepsy and pain management. Strong financial position supports growth, with new launches and strategic collaborations planned.
NeuroOne Medical Technologies Transcript: Small-Cap Virtual Conference
A next-generation electrode platform enables less invasive, combined diagnostic and therapeutic procedures for neurological disorders, supported by FDA-cleared products and strategic partnerships. Strong financials, expanding markets, and ongoing innovation position the company for significant growth and reduced investment risk.
NeuroOne Medical initiated with a Buy at Maxim
Maxim initiated coverage of NeuroOne Medical (NMTC) with a Buy rating and $3 price target
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
EDEN PRAIRIE, Minn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...
NeuroOne Medical receives FDA 510k clearance for OneRF
NeuroOne Medical (NMTC) Technologies has received U.S. Food and Drug Administration, FDA, clearance to market its OneRF Trigeminal Nerve Ablation System for use in procedures to create radiofrequency ...